Scientists Breaking the Respiratory Disease Barrier

Leadership

A new way of approaching the problem

Aeon Respire's founders spent over 10 years studying and thinking about the roots of inflammatory and obstructive respiratory disease. Through this work they developed a deep appreciation for the importance of structural lung cells as both the instigators and mediators of airway narrowing in disease. This led to the prioritization of a new kind of target that's expressed in both the smooth muscle and the epithelium. They're now bringing their extensive expertise in this area to advance a better approach to achieve long-lasting and robust breathing health for millions.

John Sullivan
Founder, Chief Executive Officer, CSO
Read Bio
Dirk Smith
Founder, VP of Research & Development
Read Bio
Andreas Hochheimer, PhD
Chief Operating Officer and CTO
Read Bio
Stephen Liggett, MD
Associate VP, Research, USF Health Scientific Advisory Board
Read Bio
Longbin Liu, PhD
Scientific Advisor, Chemistry
Read Bio
Mark Osier, PhD, DABT
Inhalation Toxicology
Read Bio

Leadership

Clinical

Clinical

Supported by world-class expertise in research and clinical drug development

Aeon Respire is building a strong supporting cast of physicians and scientists that represent the best in their field. We've sought the top thinkers in airway cell biology and respiratory clinical development. Our operational model is nimble with a deep field of noteworthy expertise.

Dr. Stephen Ruoss, MD
Professor of Medicine, Pulmonary and Critical Care, Stanford
(NCFB)
Dr. Jose Herazo-Maya, MD
Chief of Pulmonary, Director Ubben Center for Pulmonary Fibrosis, USF Health
(IPF)
Dr. Peter Bradding, MD
Professor, Chair of Respiratory Medicine, University Leicester, UK
(Asthma, IPF)
Dr. Reynold Panettieri, MD
Vice Chancellor for Translational Medicine, Rutgers
(Asthma, COPD)
Some of our partners

Some of our partners